Back to search results

PROPER-GERD: Optimizing Bravo pH Monitoring for Reflux Testing

This study, PROPER-GERD, is looking at a better way to place a device called Bravo pH monitoring to diagnose GERD (Gastroesophageal Reflux Disease), which causes symptoms like heartburn. Researchers are testing if placing the Bravo pH probe 1 cm above the SCJ (a point in your esophagus) is more accurate than the standard placement of 6 cm. You might be able to join if you are an adult between 18 and 90 years old, have typical GERD symptoms, and haven't had certain surgeries. The study will measure how well each placement detects acid reflux over 96 hours. The study is currently unclear on its recruitment status and plans to enroll 80 participants.

Study design
This is a prospective, within-subject controlled study. It involves 80 participants and compares two different placements of the Bravo pH probe at the same time.
What's involved
You would undergo one Bravo pH monitoring session where two probes are placed during an endoscopy. You will monitor your symptoms for 96 hours using a diary.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint measures pH levels over a 96-hour monitoring period (Days 0-Day 4).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07716592

PROPER-GERD: A Prospective Crossover Study to Evaluate Probe Placement Optimization for Reflux Testing in Women and Lower-BMI Patients

Not Yet Recruiting
NAAges 18–90InterventionalDiagnostic
University of Chicago
~80 participants
Updated 2026-07-21 on ClinicalTrials.gov
What's tested:Bravo pH monitoring sessions

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Diagnostic sensitivity of Bravo pH testing defined by total percent time pH < 4 over the 96-hour monitoring period
Measured over Days 0-Day 4

Conditions

GERD

Explore related trials

Gastroesophageal Reflux Disease

Where it's being run

1 sites across 1 states
Illinois1

Who to contact

Yalini Vigneswaran
[email protected]
773-702-6337
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adults aged 18-90
Typical GERD symptoms (heartburn, regurgitation, chest discomfort)
No prior foregut surgery
Ability to undergo endoscopy with sedation and consent

Exclusion

Known motility disorders (e.g., achalasia)
Barrett's esophagus \>3 cm
Pregnancy
Chronic opioid use
Inability to tolerate endoscopy or EndoFLIP
Presence of large type III or IV paraesophageal hernia
Previous esophageal or gastric surgery, including previous hiatal hernia repair

What this trial measures

  • Diagnostic sensitivity of Bravo pH testing defined by total percent time pH < 4 over the 96-hour monitoring periodDays 0-Day 4

    One probe will be placed 1 cm above the SCJ (distal position), and the other 6 cm above the SCJ (standard position), using traditional SCJ visualization for placement to measure reflux episodes.